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Abstract
Supporting the wound healing process by sending the appropriate cytokine signals
can shorten healing time and overcome chronic inflammation syndromes. Even
though adhesion peptides consisting of Arg-Gly-Asp (RGD) are commonly used to
enhance cell-surface interactions, peptide-mediated cytokine delivery has not been
widely exploited so far. Cytokines interact with high affinity with their cognitive
receptors but also with sulfated glycosaminoglycans (GAGs), both of which form a
base for incorporation of cytokines into functional biomaterials. Here, we report on a
mussel-derived surface coating as a prospective cytokine delivery system using
covalently bound heparin mimetics, receptor-derived chemokine-binding peptides,
and heparin-binding peptides (HBP). The latter enabled non-covalent immobilization
of heparin on the surface followed by chemokine binding and release, whereas the
former allowed direct non-covalent chemokine immobilization. The peptide displayed
excellent binding to custom-made polystyrene 96-well plates, enabling convenient
testing of several compounds. Released chemokine successfully induced migration in
Jurkat cells, especially for the non-covalent heparin immobilization approach using
HBPs as evaluated in a transwell assay. In comparison, heparin-mimetic coatings,
comprised of sulfated peptides and GAG derivatives, proved less efficient with
respect to amount of immobilized chemokine and migratory response. Thus, our
study provides a roadmap for further rational optimization and translation
into clinics.
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1 | INTRODUCTION
Chemokines are a family of small 8–12 kDa proteins that mediate
migration and arrest of their target cells. They are crucial players in
tissue regeneration as they orchestrate the recruitment of various cell
types to the wound site, modulating the immune response and
directing angiogenesis. CXC chemokine ligand 12 (CXCL12) or stromal
cell-derived factor 1α (SDF-1α) is a pleiotropic cytokine that signals
through its G protein-coupled receptors CXCR4 and CXCR7 and acts
as a chemoattractant. In adult organisms, CXCL12 promotes
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angiogenesis, the recruitment of hematopoietic stem and progenitor
cells, immune cell trafficking, and neuronal regeneration
(Guyon, 2014; Liekens, Schols, & Hatse, 2010). Thus, the chemokine
is involved in various stages of wound healing including homeostasis,
inflammation, and proliferation (Ratajczak et al., 2006), making it an
appealing component of biomaterials in tissue engineering. However,
the development of suitable delivery strategies remains an ongoing
field of research. Simple adsorption to the material already promotes
tissue regeneration (Ji et al., 2013), but stabilization against rapid pro-
tein clearance and a controlled release to reduce side effects is desir-
able. In opposition, covalent immobilization approaches require
protein engineering to incorporate functional groups for surface bind-
ing and cleavable linkers for protein release (Steinhagen et al., 2014),
which can alter protein activity. Thus, affinity-based delivery systems
are to be exploited, where a binding ligand is immobilized to the mate-
rial, which then reversibly binds the unmodified chemokine.
In the extracellular matrix, glycosaminoglycans (GAGs) like hepa-
rin and heparan sulfate represent the most important binding partners
of CXCL12. Stabilization by GAGs is essential for the formation of
chemotactic gradients and protects the chemokine from inactivating
posttranslational modifications (Janssens, Struyf, & Proost, 2018). This
heparin-binding affinity can be exploited for the delivery by covalent
or non-covalent incorporation of heparin into biomaterials (Vulic &
Shoichet, 2014). Heparin-binding peptides (HBPs) contain a number
of basic residues to interact with the negatively charged GAGs
and therefore offer the possibility to immobilize heparin by electro-
static interaction (Cardin & Weintraub, 1989; Sakiyama-Elbert &
Hubbell, 2000). In these cases, the cytokine as well as the mediating
GAG will be released over time. Specifically functionalized heparin or
heparin analogs can mediate orthogonal conjugation to the material.
Sulfated hyaluronic acid (sHA) derivatives have been developed as
heparin-like protein-binding polymers that, when applied as high
molecular weight sHA or even as short oligomeric compounds, have
proven to bind CXCL12 (Köhling et al., 2019; Purcell et al., 2014).
Another possibility is the complete replacement of the sugar with
peptidic compounds. However, for explicit delivery of CXCL12, only
receptor-derived peptides (RDPs) are known so far (Peled,
Eizenberg, & Vaizel-Ohayon, 2012), some of which include also
posttranslational tyrosine sulfation (Veldkamp, Seibert, Peterson,
Sakmar, & Volkman, 2006). For the delivery of other cytokines, a
number of heparin-mimetic peptides (HMPs) are known. Sulfates are
included either by O-sulfation of serine and threonine residues or by
incorporation of sulfotyrosines. Maynard and Hubbell identified the
consensus sequence SY*DY*G, where Y* is a sulfotyrosine, which was
confirmed to bind vascular endothelial growth factor (VEGF;
Maynard & Hubbell, 2005), transforming growth factor β, and
bone morphogenetic protein 4 (Hendrikse, Spaans, Meijer, &
Dankers, 2018). Within another approach, sulfobenzoic acid (sba) is
coupled to lysine side chains to incorporate sulfate groups into a
molecular brush (Mammadov et al., 2011). The peptide EGDK(sba)S
was shown to bind VEGF, hepatocyte growth factor, and fibroblast
growth factor 2 (Mammadov, Mammadov, Guler, & Tekinay, 2012) to
enhance angiogenesis and wound healing.
Within the present study, affinity-based delivery strategies for
CXCL12 inspired by extracellular matrix-proteoglycan interactions
were investigated. Here, functional peptide coatings were used to
immobilize GAGs and GAG mimetics onto a polymer surface in order
to provide a prospective chemokine delivery system that is easily
prepared, purified, and analyzed. This was enabled by incorporation of
L-3,4-dihydroxyphenylalanine (DOPA), a nonproteinogenic amino acid
identified in the byssus of blue mussels (Waite & Tanzer, 1981), into
surface-binding peptides. In this work, application of the catechol-
based coating was shown to go beyond metal oxide surfaces, where
display of cell adhesives promoted osseointegration and
endothelialization (Clauder et al., 2019; Pagel et al., 2016). Using the
peptide as a modifiable anchor provided a platform to compare HBPs,
subsequently loaded with heparin, sHA derivatives, and sulfated
peptides but also receptor-derived chemokine-binding peptides for
CXCL12 binding. Finally, gradient formation was investigated by
transwell migration studies to test for effective cell recruitment.
2 | MATERIALS AND METHODS
2.1 | Chemicals
Fluorenylmethoxycarbonyl (Fmoc)–protected amino acids, resins,
and coupling reagents were purchased from IRIS Biotech. N,N-
dimethylformamide (DMF), dichloromethane (DCM), and N-methyl-
2-pyrrolidon (NMP) were purchased from Biosolve, whereas
acetonitrile (ACN) was obtained from VWR. Hyaluronic acid (HA, from
Streptococcus, MW = 1,100 kDa) was obtained from Aqua Biochem.
Sulfo-N-succinimidyl 4-maleimidobutyrate (XLINK) was from Bachem,
and monomeric avidin agarose beads was from Pierce. Tris
(hydroxymethyl)aminomethane (Tris) and bovine serum albumin
(BSA) were obtained from Roth, and antibodies from Santa Cruz
Biotechnology, Inc. 3,30,5,50-Tetramethylbenzidine (TMB) was from
Merck and HCl from Grüssing. RPMI 1640 was purchased from Lonza
and fetal calf serum (FCS) from Biochrome. All other reagents were
obtained from Sigma-Aldrich.
2.2 | Peptide synthesis
All peptides were synthesized by a combination of manual couplings
and automated solid-phase peptide synthesis using a Syro I peptide
synthesizer (MultiSynTech) under standard Fmoc/tert-butyl (tBu)
conditions. The Nα-Fmoc-deprotection was achieved with piperidine
in DMF, and amino acids were activated with equimolar amounts
of N,N-diisopropylcarbodiimide (DIC) and 1-hydroxybenzotriazole
(HOBt) or hydroxyiminocyanessigsäureethylester (oxyma), respec-
tively. The peptides HBP-N3 and HBP2-N3 were produced in the
synthesizer on Rink amide resin and N-terminally modified with
ε-azido-L-lysine. Heparin-mimetic peptide 1 (HMP1) and HMP2 as
well as motif repetitions were likewise produced automatically,
whereby Fmoc-L-Lys(Dde)-OH was incorporated at future sulfation
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sites. After N-terminal trityl-protection or acetylation, selective
deprotection of the lysine side chain was achieved with 3% hydrazine
in DMF. sba was coupled in two-fold excess with equimolar amounts
of 1-[bis (dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]
pyridinium 3-oxide hexafluorophosphate and one equivalent N,N-
diisopropylethylamine overnight. RDP was likewise produced auto-
matically on Rink amide resin. The mussel-derived peptide
(MP) derivatives were analogously synthesized as described elsewhere
(Pagel et al., 2016). MP(+) and MP(−) were produced by elongation
with Fmoc-L-aminohexanoic acid and subsequently biotinylated with
HOBt/DIC in NMP. Conjugation of MP with the HBPs HBP-N3 and
HBP2-N3 by Cu(I)–catalyzed azide alkine cycloaddition was likewise
performed as described by Pagel et al. (Pagel et al., 2016). Thiol- and
maleimide-functionalized compounds were combined by Michael
addition reaction, which was carried out for at least 2 h in degassed
sodium phosphate buffer pH 6.8. Successful conjugation was
observed by a retention time shift during reversed-phase high-
performance liquid chromatography (RP-HPLC) analysis, whereby in
all cases, less than 2% unfunctionalized MP remained.
2.3 | Full cleavage and peptide purification
Full cleavage of the peptides was achieved by incubation with a
mixture of trifluoroacetic acid (TFA) and scavenger for 3 h at room
temperature, shaking. For HBPs, 90% TFA and 10% water was used.
The sulfated peptides were cleaved using 95% TFA and 5%
triisopropyl silane/water (1:1, v/v). RDP was cleaved with 90% TFA
and 10% thioanisole/ethanedithiole (7:3, v/v). Peptides were precipi-
tated and washed with ice-cold diethyl ether. Peptide purification was
carried out by preparative RP-HPLC on a Phenomenex Kinetex
XB-C18 column (100 Å, 5 μm, 250 × 21.2 mm) using linear gradients
of Eluent B in Eluent A (A: 0.1% TFA in water; B: 0.08% TFA in ACN).
Analytical identification of the peptides was performed by matrix-
assisted laser desorption/ionization time of flight mass spectrometry
(MALDI-ToF-MS; Bruker Daltonics) and electrospray ionization-Ion
Trap MS (Bruker Daltonics), and observed m/z values matched the
calculated molecular weights. Final purity was confirmed by analytical
RP-HPLC on two of the three following columns: Phenomenex Jupiter
Proteo column (90 Å, 4 μm), Agilent Technologies VariTide RPC
column (200 Å, 6 μm), or Phenomenex Jupiter C18 column (300 Å,
5.3 μ) using linear gradients of Eluent B in Eluent A.
2.4 | Synthesis of sulfated GAG derivatives and
coupling to MP
The fully sulfated nonasulfo-tetrahyaluronan-polyethylene glycol
(PEG)-thiol (sHA1) was obtained by tris-(2-carboxyethyl)-phosphane
(TCEP)–mediated reduction of the bivalent octadeca-sulfo-disulfide
(9s-HA-4-S-PEG-S-)2 that was synthesized as reported previously
(Köhling et al., 2019). The disulfide reduction was performed as




fide, (9s-HA-4-S-PEG-S)2 (49 mg, 12.6 μmol) was dissolved in 2 ml
of degassed phosphate buffered saline (PBS; 0.2 M, pH: 7.5) and
stirred under argon atmosphere. TCEP (9 mg, 31.6 μmol) was added
and the reaction mixture was stirred for 5 min at room temperature.
Subsequently, the mixture was transferred into a dialysis tube
(cellulose acetate, molecular weight cut-off = 1,000 Da) and exces-
sively dialyzed against degassed water for 1 day. The product was
transferred from the dialysis tube into a flask and freeze-dried to
yield sHA1 as a white powder (47 mg, 96%). 1H NMR (700 MHz,
D2O) δ [ppm] = 5.18 (d, J = 4.1 Hz, 1H), 5.06–5.03 (m, 2H), 4.93
(d, J = 6.7 Hz, 1H), 4.87–4.83 (m, 2H), 4.79 (d, J = 10.4 Hz, 1H),
4.56 (dd, J = 11.4, 2.2 Hz, 1H), 4.55–4.52 (m, 2H), 4.47 (t, J = 4.3 Hz,
1H), 4.43 (d, J = 6.7 Hz, 1H), 4.39 (dd, J = 6.7, 2.6 Hz, 1H), 4.30
(t, J = 9.4 Hz, 1H), 4.27 (t, J = 9.2 Hz, 1H), 4.23–4.15 (m, 3H), 4.08
(dd, J = 11.5, 7.9 Hz, 1H), 4.00 (t, J = 9.3 Hz, 1H), 3.91–3.86
(m, 3H), 3.82 (s, 1H), 3.77–3.70 (m, 2H), 3.70–3.63 (m, 6H), 2.93
(dt, J = 13.6, 6.6 Hz, 1H), 2.84 (dt, J = 14.1, 6.3 Hz, 1H), 2.69
(t, J = 6.3 Hz, 2H), 2.11 (s, 3H), 2.07 (s, 3H).; 13C NMR (176 MHz,
D2O) δ [ppm] = 174.72, 174.51, 174.04, 100.75, 100.09, 99.48,
84.79, 79.76, 79.04, 78.84, 78.05, 77.97, 77.23, 76.87, 76.59,
75.61, 75.40, 74.87, 72.92, 72.23, 70.17, 69.51, 69.22, 67.93,
67.59, 55.77, 54.56, 30.28, 28.14, 23.22, 22.99, and 22.77. Coupling
to MP-Male was performed as described for the sulfated peptides
and monitored by RP-HPLC.
Low-molecular-weight HA samples (HA1, MW = 43 kDa, and
HA2, MW = 115 kDa) were prepared by thermal degradation of HA
in an autoclave according to a published protocol (Kunze
et al., 2010). The sulfated polymer derivatives sHA2 and sHA3 were
synthesized by sulfation of the degraded HA1 and HA2 samples
with SO3-pyridine (OH/SO3 = 1:15) for sHA2 and SO3-DMF (OH/
SO3 = 1:20) for sHA3, respectively. Introduction of amino groups
proceeded by reductive amination with ethylendiamine
dihydrochloride (EDA × 2 HCl) and NaCNBH3 as follows: a 10 mg/
ml aqueous solution of sHA was saturated with EDA × 2 HCl over
several hours. After pH adjustment to 7.4, NaCNBH3 was added
and the mixture stirred for 3 days. Subsequently, the solution was
dialyzed against 0.125 M aqueous NaHCO3-solution for further
3 days following dialysis against water. The final products were
lyophilized and dried. The contents of amino groups were deter-
mined by Kaiser test. Analytical data of the prepared GAG deriva-
tives are summarized in Table S2. Amine-functionalized sHA
derivatives were initially reacted with 5 eq XLINK in 10 mM sodium
phosphate buffer pH 8 at 4C overnight. After size exclusion centri-
fugation (7,500 g, 15 min) with a cut-off at 10 and 30 kDa, respec-
tively, to separate unreacted crosslinker, the compounds were
subsequently coupled with 5 eq biotinylated (Bio)-MP(Ala) by
Michael addition reaction as described above. Excess Bio-MP(Ala)
was again removed by size exclusion chromatography. The orthogo-
nality of the reaction was monitored on a Varian Cary® 50 UV–Vis
Spectrophotometer measuring the absorption spectrum between
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200 and 300 nm. The amount of peptide was determined via the
absorption of the DOPA units at 280 nm and a linear standard
curve obtained from MP (r2 = 0.99). Finally, MP-XLINK-sHA2/3
were purified using affinity chromatography. Monomeric avidin aga-
rose beads were washed and loaded with the reaction mixture as
described in the manufacturer's protocol. Finally, peptide-crosslinked
GAG were eluted using 2 mM biotin in PBS.
2.5 | Peptide immobilization
Serial dilutions of MP(+) and MP(−) in 10 mM Tris buffer pH 7.6 were
incubated in polystyrene 96-well plates overnight at room tempera-
ture and shaking. Afterwards, unbound peptide was washed off with
tris-buffered saline-tween20 (TBS-T; 50 mM Tris, 150 mM NaCl,
0.1% tween20, pH 7.6). Detection of bound MP was performed via
the biotin tag in an enzyme-linked immunosorbent assay (ELISA)–like
assay, as described previously (Hassert et al., 2012). The experiment
was performed three times in triplicates, and data are shown as
mean ± standard error of the mean (sem).
For further investigations, a 1 μM peptide dilution in 10 mM Tris
buffer pH 7.6 was incubated on the microtiterplate overnight. After
washing with TBS-T, incubation with heparin and/or CXCL12
continued.
2.6 | Heparin binding
MP-HBP and MP-HBP2 were immobilized onto 96-well plates over-
night. Subsequently, wells were incubated with 1 μM biotinylated por-
cine heparin (bio-Hep, MW = 15 kDa, DS = 1.8–2.2) in TBS buffer
(50 mM Tris, 150 mM NaCl, pH 7.6, 8.3 or 8.9) for 1 h. Detection
occurred via the biotin tag as described above. The data are derived
from at least three independent experiments performed in triplicates
and displayed as mean + sem.
2.7 | CXCL12 binding
Full-length CXCL12, carrying a C-terminal methionine due to
Escherichia coli expression, was produced, refolded, and purified as
described previously (Spiller et al., 2019). Peptides were immobilized
and subsequently loaded with 1 μM heparin (MW = 15 kDa, DS = 1.8–
2.2) for 1 h and 1 μM CXCL12 for 2 h. After another washing step
with TBS-T, wells were blocked with 10% BSA in TBS and bound
CXCL12 was detected using mouse-anti-SDF-1 (1:500 in 1% BSA in
TBS) and goat-anti-mouse-IgG-horseradish peroxidase (HRP; 1:5,000
in TBS). Addition of the peroxidase substrate TMB and halting the
conversion after 5 min with 1 M HCl enabled quantitative readout at
450 nm absorption (infinite M200, Tecan). The experiment was
performed at last twice in triplicates. Data are normalized to
MP-HBP = 1 and represented as mean + sem.
2.8 | Migration
The lower chambers of a 96-well high throughput screening transwell
plate (5 μM pore size, Corning) were coated with peptide, heparin,
and CXCL12, as described earlier. Rinsing several times with PBS
removed remaining TBS-T from the washing steps. Jurkat cells (kindly
gifted by the Institute of Immunology, University Hospital Leipzig)
were kept in RPMI 1640 with 10% FCS at 37C in a humidified atmo-
sphere containing 5% CO2. For migration assays, cells were spun
down and resuspended in RPMI 1640 containing 2% FCS (migration
media). 4 × 105 cells per 100 μl were loaded to the upper chambers.
The lower chambers were filled with 250 μl migration media, and
50 nM CXCL12 were used as positive control. After incubation at
37C for 2 h, 100 μl sample per well was mixed with 100 μl 0.5%
trypan blue in PBS. The number of migrated cells was determined at a
Spark plate reader (Tecan) using the automatic cell-counting applica-
tion (Cell Chip). Data were obtained from at least three independent
experiments performed in duplicates and is shown as mean + sem.
2.9 | Statistical analysis
Statistical analysis was implemented with Prism 5.0 (GraphPad), and
significances were determined with one-way ANOVA followed by
Newman–Keuls multiple comparison test, except for surface binding
studies, where a two-way ANOVA following Bonferroni posttests
was applied.
3 | RESULTS
3.1 | DOPA-containing peptides efficiently coat
polystyrene surfaces
Wound healing and regeneration are very complex and highly orches-
trated processes. Numerous cell types are involved, whose function
and timing are of utmost importance. Herein, cytokines execute
important messenger functions, enabling the communication that
regulates inflammatory processes, cell migration, cell activation, and
cell survival. Releasing CXCL12 into acute or chronic wounds might
help improve healing times due to its beneficial effect on revasculari-
zation and modulating role in immune cell recruitment. In our
approach, we used a peptide derived from the marine blue mussel
(MP) as a platform for presenting heparin-binding/mimetic sequences
that allow sequestration of the chemokine from a solid support
(Figure 1a). DOPA was incorporated for immobilization on polystyrene
surfaces (PS), whereas orthogonal reaction groups enabled modifica-
tion with peptides and GAGs. An N-terminally biotin-tagged
derivative, termed MP(+), allowed detection of immobilized peptide
with horseradish peroxidase-conjugated streptavidin (Strep-POD). In
the control peptide MP(−), DOPA was replaced with tyrosine.
Concluding from an ELISA-like assay, DOPA generally enhanced the
amount of immobilized peptide to standard 96-well PSs in comparison
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with the control peptide. A binding affinity study revealed a 20-fold
shift in EC50 between the peptides (Figure 1b).
3.2 | Functional click chemistry enables the
generation of heparin-binding and heparin-mimetic
coatings
The two approaches described in this study based on cytokine-GAG-
interactions to deliver CXCL12 from a peptidic surface coating are dis-
played schematically in Figure 2. On the one hand, a HBP coating
electrostatically immobilizes heparin and subsequently delivers
heparin-binding cytokines (Figure 2a, left). On the other hand, HMPs
and sulfated GAG derivatives were covalently coupled to bind and
release heparin-binding cytokines (Figure 2b, left). Although the
DOPA units of MP anchor the coating to the surface, modification
with functional peptides, GAGs, or GAG mimetics was achieved by
introduction of orthogonal reaction groups. To enable the non-
covalent immobilization of heparin, the HBPs HBP and HBP2 were
coupled to propargylglycine by Cu(I)-catalyzed azide-alkine cycloaddi-
tion (Figure 2a, middle). To investigate heparin binding, a biotinylated
heparin derivative was incubated on MP-HBP- and MP-HBP2-coated
surfaces, respectively, and detected by Strep-POD (Figure 2a, right).
Both peptides were found to efficiently immobilize heparin in
comparison to unfunctionalized MP, whereby the elongated sequence
HBP2 gave a 2.8-fold higher signal than the single motif HBP. This
loading efficiency was also observed when tested at basic conditions,
as chronic wounds can have pH values up to 8.9 (Figure S1; Tsukada,
Tokunaga, Iwama, & Mishima, 1979; Wilson, Henry, Quill, &
Byrne, 1979).
In comparison with the dual-affinity approach, which combines
HBP and heparin for CXCL12 release, heparin-mimetic coatings were
synthesized (Figure 2b). These coatings comprise small peptides as
well as short and long sHA derivatives. For the generation of sulfated
peptides, sba was coupled to lysine side chains of the sequence
EGDKS, similar to a procedure reported by Mammadov et al.
(Mammadov et al., 2011). This gave stable compounds that retained
sulfation even under highly acidic conditions as during deprotection,
full cleavage, and preparative HPLC. In contrast, direct incorporation
of sulfotyrosine into the growth factor-binding sequence SYDYG
proved to be too acid labile, especially when more than one sulfate
group was incorporated. Accordingly, these residues were replaced
with lysine and the peptide was analogously sulfated using sba
(Figure 2b, right). During conjugation to MP-Male by thiol-maleimide
Michael addition reaction (Figure 3a), an excess of sulfated peptide
quantitatively consumed the MP. Thereby, less than 2% unmodified
peptide remained, as monitored by RP-HPLC. A list of all synthesized
precursor peptides and conjugates as well as analytical characteriza-
tion is displayed inTable S1.
Beyond the synthesis of sulfated peptides, HA derivatives
of differing size were tested: a fully synthetic nonasulfated
tetrasaccharide (sHA1) and two chemically sHA derivatives of lower
(sHA2) and slightly higher molecular weight (sHA3; Figure 2b,
bottom). Although the short tetrasaccharide was equipped with a
thiol functionality that enabled conjugation to MP-Male analogously
to the sulfated peptides (Figure 3a), sHA2 and sHA3 displayed an
ethylene diamine group at the reducing end. A crosslinker (XLINK)
enabled conjugation to MP (Figure 3b). To prevent unspecific
crosslinking, the surface-binding peptide was depleted of its
lysine residue (MP(Ala)) and additionally equipped with a biotin-tag
(Bio-MP(Ala)) for subsequent purification by monomeric avidin affin-
ity chromatography. To verify whether the conjugation reaction was
indeed specific, sHA2/3 and the MP were incubated with or
without preceding XLINK conjugation. Absorption spectra of the
reaction mixtures were recorded, whereby the absorption at
280 nm correlates to the DOPA residues within the peptide (Figure;
4a). In the sample without XLINK, only a small amount of peptide
F IGURE 1 (a) Chemical structure of mussel-derived peptide (MP(+)). The L-3,4-dihydroxyphenylalanine (DOPA) units for surface binding are
highlighted in green, and the biotin-tag for detection in gray. Functional groups for peptide conjugation by thiol-maleimide Michael addition
reaction and Cu(I)-catalyzed azide-alkine cycloaddition (CuAAC) are highlighted in red and blue, respectively. (b) Surface binding of the mussel-
derived anchor peptide MP(+) to polystyrene. MP(−), a tyrosine-containing peptide analog, shows a 20-fold loss in affinity in comparison to the
DOPA-containing derivative. n = 3, *p ≤ 0.05, ***p ≤ 0.001 with respect to MP(−) [Colour figure can be viewed at wileyonlinelibrary.com]
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was detected, although the peptide was about 50-fold enriched
when a preincubation with XLINK had occurred (Figure 4b).
3.3 | High CXCL12 surface loading and subsequent
cell migration achieved with HBP-heparin-complexes
For investigation of CXCL12 binding, the different MP-conjugates
were immobilized onto 96-well plates, and heparin-binding conjugates
were additionally loaded with heparin. Subsequently, 1 μM CXCL12
was incubated on all surfaces, and retained protein was detected by
specific antibodies (Figure 5a). With respect to unfunctionalized MP,
five coatings were identified for CXCL12 binding: MP-RDP, MP-
XLINK-sHA2, MP-XLINK-sHA3, MP-HBP-heparin, and MP-HBP2-
heparin. Herein, significantly higher amounts of protein were retained
using the heparin binding approach. Within this scope, increased
heparin affinity by sequence elongation (HBP2) enhanced CXCL12
binding by two-fold. Next, we examined whether the
CXCL12-binding coatings were able to induce migration in Jurkat
cells, as chemotactic gradient formation and the recruitment of
hematopoietic stem cells are key functions of CXCL12 (Figure 5b).
However, only coatings with higher chemokine loading were able to
exceed the threshold for migration induction in CXCR4-expressing
cells. This was accomplished by both MP-HBP-heparin-complexes,
which recruited around 15% of the cells and were on par with the
positive control. However, there were no differences detectable
between MP-HBP and MP-HBP2 even though CXCL12 loading was
twice as high on the latter.
F IGURE 2 Binding and release strategies for cytokine delivery. (a) Heparin-binding peptides (HBP) enable the non-covalent immobilization of
heparin and subsequent coating with cytokines. Although the peptide remains anchored to the surface, heparin and the cytokine are both
released. Sequences of HBP and schematic representation of the conjugation to the mussel-derived peptide (MP) by CuAAC (middle); Heparin
binding to immobilized MP-HBP and MP-HBP2 as investigated in a biotin ELISA-like assay (right). n ≥ 3,
*p ≤ 0.05. (b) Covalently coupled heparin-
mimetic agents release only the immobilized cytokine. Sequences of sulfated heparin-mimetic peptides (HMPs) and a CXCR4 receptor-derived
peptide (RDP; right). Structures of the short persulfated hyaluronic acid derivative sHA1 (MW = 1.902 kDa, DS = 5.5) and higher molecular weight
sulfated hyaluronic acid derivatives sHA2/3 (sHA2: MW = 21.4 kDa, DS = 3.5; sHA3: MW = 87.0 kDa, DS = 3.4; bottom). K(N3), ε-azido-L-lysine;
CuAAC, Cu(I)-catalyzed azide-alkyne cycloaddition; β, L-β-alanine; sba, 4-sulfobenzoic acid; Ac, acetate [Colour figure can be viewed at
wileyonlinelibrary.com]
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4 | DISCUSSION
Therapeutic chemokine delivery in wound healing can be achieved in
different ways. The respective chemokine can be incorporated into
hydrogels and be released upon slow degradation of the biomaterial
(Baumann et al., 2012). Also, it can be immobilized covalently on a
solid support using an enzyme-cleavable linker mediating release by
proteolytic attack (Steinhagen et al., 2014). In contrast to that, we
have developed a modular peptide system consisting of a surface
binding peptide that can be decorated with different cell recruiting
moieties using bioorthogonal reactions (Clauder et al., 2019; Pagel
et al., 2016). The advantage apart from being modular is that the pep-
tide components are build up by solid-phase peptide synthesis
allowing site-selective incorporation of nonnatural amino acids and
nonamino acid components as well as full control over identity and
homogeneity of the final product using standard RP-HPLC and mass
spectrometry. In this study, we aimed to apply this approach in order
to create a prospective delivery system for CXCL12 using affinity-
based immobilization of the chemokine. Our focus was not only based
on the final outcome of CXCL12 release but also on the feasibility of
the production of the release system. This led us to the design, on the
one hand, of a peptide carrying covalently attached heparin mimicking
moieties and, on the other hand, heparin-binding peptides allowing
for non-covalent immobilization of heparin followed by chemokine
binding. These approaches enabled purification by RP-HPLC and
identification by mass spectrometry without the need of any further
verification of product homogeneity.
A prerequisite for the stable immobilization of CXCL12-binding
coatings is a strong surface anchoring. This can be achieved by a
bioinspired approach adapted from mussels, which adhere to virtually
all kinds of substrates even in high tide and strong waves. A derived
peptide coating was now shown to bind to standard PS 96-well
plates, which is convenient for fundamental investigations and
high-throughput studies. Binding affinity studies demonstrated a
20-fold lower EC50 for the DOPA-containing peptide in comparison
with the tyrosine-containing control. For PS surfaces, this can be ratio-
nalized by a combination of hydrophobic, cation–π, and π–π stacking
interactions (Lu et al., 2013). Although π–π stacking is based on inter-
actions between the aromatic groups of the MP and the phenyl
groups of the PS, OH–π interactions might additionally strengthen the
binding and explain the observed differences between the DOPA-
and the tyrosine-containing peptide (Wang & Xie, 2010). The
F IGURE 3 Schematic representation of the conjugation of heparin-mimetic compounds to mussel-derived peptide (MP). (a) Conjugation of
heparin-mimetic peptide (HMP), receptor-derived peptide (RDP), and sHA1 via Michael addition of a thiol to an N-terminal maleimide group.
(b) Conjugation of sHA2/3 to the N-terminal cysteine using a sulfo-N-succinimidyl 4-maleimidobutyrate (XLINK) crosslinker [Colour figure can be
viewed at wileyonlinelibrary.com]
F IGURE 4 (a) Absorption scan of mussel-derived peptide
(MP) and sHA3, incubated with and without crosslinker. Water and
sHA3 alone served as negative controls. (b) Peptide content prior to
purification by biotin-avidin affinity chromatography as determined
via absorption at 280 nm [Colour figure can be viewed at
wileyonlinelibrary.com]
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positively charged lysine residue provides additional binding proper-
ties via cation–π interactions and helps to abstract the hydration
layer, enabling a tight binding of DOPA to the surface and limiting its
oxidation (Maier, Rapp, Waite, Israelachvili, & Butler, 2015).
We then equipped MP with HBPs. Reported literature suggests
that these peptides electrostatically interact with the negatively
charged sulfate and carboxyl groups of heparin via the basic amino
acids histidine, arginine, and lysine (Cardin & Weintraub, 1989). This
was demonstrated for MP-HBP, and it is assumed that elongation of
this sequence increases possible interaction sites and therefore
retains significantly more heparin on the surface, as shown for
MP-HBP2. The underlying sequence FHRRIKA is derived from the
bone sialoprotein (Rezania & Healy, 1999), whereas others are based
on antithrombin III or the heparin-interacting protein. Investigation of
consensus sequences identified clusters of one to three basic amino
acids with one or two interpolated hydrophobic residues (Cardin &
Weintraub, 1989). This matches the natural binding partner heparan
sulfate that displays regions of varying charge densities. For optimal
GAG binding, basic and hydrophobic residues should likewise
alternate (Fromm, Hileman, Caldwell, Weiler, & Linhardt, 1995). In
addition, the secondary structure also needs to be taken into
consideration, as heparin binding can induce conformational changes
and align the basic residues in spatial proximity facing the GAG
(Capila & Linhardt, 2002).
Subsequently, CXCL12 binding was confirmed on the peptide-
heparin-complexes. Notably, the higher heparin-binding capacity of
MP-HBP2 also retained significantly more CXCL12 in comparison with
MP-HBP. Tight packing of the small peptides on the surface and high
loading with heparin might be an explanation. Surprisingly, both coat-
ings proved to be equal, when studying cell recruitment in a transwell
assay. However, chemoattraction works in a broad range of
concentrations as cells are able to compare signals reaching front and
rear of the membrane, possess the ability to amplify detected differ-
ences, and perform background subtraction of uniform receptor-
occupancy (Kutscher, Devreotes, & Iglesias, 2004). Another reason for
the unexpected indifference between the two coatings could lie
within the heparin sequestration. In addition to higher amounts of
chemokine, more heparin is simultaneously released from MP-HBP2.
Even though GAG and receptor-binding sites are clearly separated in
CXCL12 and the protein remains active in a complex (Laguri,
Arenzana-Seisdedos, & Lortat-Jacob, 2008; Sweeney, Lortat-Jacob,
Priestley, Nakamoto, & Papayannopoulou, 2002), soluble heparin
might act as a scavenger for membrane clustering. Cell-surface pro-
teoglycans locally enhance CXCL12 concentration toward the recep-
tor, and free heparin would compete with their interaction,
disconnecting the chemokine from the receptor binding site (Kuschert
et al., 1999).
In comparison with the modular approach using non-covalently
immobilized heparin for cytokine release, direct functionalization of
MP with heparin-mimetic compounds was investigated. Herein, only
the cytokine, but not the electrostatically bound heparin, would be
released into the surrounding tissues over time. Even though heparin
is extensively used as an anticoagulant, it is associated with a number
of adverse effects (Gervin, 1975). In addition, the pharmaceutical pro-
duction of heparin still solely relies on animal tissue. The process is
highly optimized and cost-effective, but quality control is difficult and
the risk of adulteration and contamination remains (Oduah, Linhardt, &
Sharfstein, 2016). Potential shortages resulting from a strong depen-
dency on porcine heparin mainly produced in China as well as animal
rights and environmental concerns demand alternative manufacturing
processes (Fu, Suflita, & Linhardt, 2016). Synthetic analogs might pro-
vide a solution and are subject to extensive research. Even though the
F IGURE 5 (a) CXCL12 binding to immobilized heparin-mimetic compounds (HMP), a receptor-derived peptide (RDP), and heparin-loaded
heparin-binding peptides (HBP) as determined by ELISA. n ≥ 2, *** represents significance to MP, p ≤ 0.001; ## represents significance to MP-HBP,
p ≤ 0.01. (b) Jurkat migration toward mussel-derived peptide coatings. The lower compartments of a transwell plate were coated with peptide
(+heparin) and CXCL12, whereas cells were seeded into the upper chambers. After 2 h incubation, the number of migrated cells was evaluated.
Medium containing 50 nM CXCL12 served as positive control. n ≥ 3, significance to uncoated, *p ≤ 0.05, **p ≤ 0.01 [Colour figure can be viewed
at wileyonlinelibrary.com]
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production can be laborious and hard to upscale, they provide better
control and higher chemical versatility for the incorporation into
functional materials. Therefore, we considered synthetic peptides as
well as HA derivatives as heparin mimetics for the covalent coupling
to MP. Previous reports had demonstrated that anionic charges solely
derived from hydroxyl and carboxyl groups are insufficient to retain
CXCL12, as demonstrated for HA in an NMR study (Panitz
et al., 2016). Consequentially, sulfated derivatives were produced.
However, HMP coatings were generally less efficient in CXCL12
binding. None of the sulfated peptides were able to accumulate
CXCL12, neither as single nor as double or triple motif, respectively.
This was unexpected, as the HMPs in principle display the three func-
tional groups of heparin—sulfates, carboxylates, and hydroxyl groups
and were confirmed to bind various cytokines in preceding studies
(Hendrikse et al., 2018; Mammadov et al., 2012; Maynard &
Hubbell, 2005). However, in these approaches, the peptides are
presented in a three-dimensional arrangement on self-assembled
nanofibers in contrast to our two-dimensional surface modification.
For the hyaluronan-based coatings, a length-dependent effect is
observed. The short tetrasaccharide in MP-sHA1 was insufficient for
immobilizing CXCL12, whereas the longer variants retained at least
small amounts of the protein. In principle, the chemokine CXCL12
dimerizes upon heparin binding (Fermas et al., 2008) and subse-
quently displays two distinct GAG-binding sites. The main binding
site, so called high-affinity heparin-binding region, is located at the
dimer interface, where a number of basic residues create a positively
charged crevice (Sadir, Baleux, Grosdidier, Imberty, & Lortat-
Jacob, 2001). Residues of the consensus sequence BBXB in the first
β-strand (Lys24, His25, and Lys27; Amara et al., 1999) as well as
spatially adjacent Arg41 and Lys43 (Sadir et al., 2001) were found to
play a major role. The second binding site, called low-affinity heparin-
binding region, includes the N-terminal loop and the α-helix.
Important residues involved in this interaction include Arg20, Ala21,
Asn30, and Lys64 (Murphy et al., 2007). To span the high-affinity
heparin binding region, 12 to 14 monosaccharide units are required
(Sadir et al., 2001). The small sulfopeptides and the tetrasaccharide
are probably too short to efficiently interact with CXCL12. However,
sequence elongation of the sulfated peptides did not enhance the
protein-binding capacity, which suggests that the defined pattern of
carboxyl and sulfate groups in heparan sulfate is not met correctly.
Studies show that especially 2-O- and N-sulfate groups contribute to
CXCL12 binding (Sadir et al., 2001) as well as 6-O-sulfation to a lesser
extent (Zhang et al., 2012). Also, L-iduronic acid provides conforma-
tional flexibility that is believed to be responsible for the variety of
proteins that can be bound specifically (Mulloy & Forster, 2000). For
the HMPs, the sulfate groups might not be displayed in the correct
conformation with respect to orientation, spacing, and distance from
the peptide backbone, as a rather long linker was introduced by using
sba. Although heparan sulfate is only moderately sulfated with an
average of one sulfate group per disaccharide, heparin is highly
sulfated with an average of 2.7 sulfate groups per disaccharide. In
comparison, the degree of sulfation of the tetrasaccharide is still
much higher, with 4.5 sulfate groups per disaccharide, which could
also be a disadvantage for the interaction. On the other hand, the dif-
ference to heparin is not as big for the higher molecular weight HA
derivatives, which display 3.5 (sHA2) and 3.4 sulfate groups (sHA3),
respectively. However, N-sulfation is completely absent in all of these
compounds. When comparing the glycosidic linkage, the monomers
of the HA derivatives are (1 ! 3)–linked and in the disaccharides
(1 ! 4), whereas in heparin and heparan sulfates, both units are
(1 ! 4)–linked. This additionally contributes to a discrepant arrange-
ment of the sulfation pattern.
Taken together, the two-step coating protocol using HBPs and
electrostatically bound heparin was most efficient in immobilizing the
chemokine CXCL12 and recruiting cells to coated surfaces. This was
rationalized by a high binding affinity toward the cytokine, owing to
an unaltered charge display of the incorporated natural heparin. In
addition, small HBP coatings can be prepared in a relatively easy fash-
ion using solid-phase peptide synthesis and bioorthogonal reactions
followed by simple RP-HPLC purification. As seen for sHA2 and
sHA3, using larger GAGs for covalent immobilization requires more
sophisticated purification protocols, and there still remains uncer-
tainty on the homogeneity and consistent functionality of the final
product. Also, HBPs reach high surface packings and are uncompli-
cated and more stable to pH changes during synthesis. By alteration
of the HBP, the amount of heparin and heparin-binding cytokines can
be tuned, catering to therapeutic purposes.
5 | CONCLUSION
In our study, a two-layer approach, where immobilized HBPs are sub-
sequently loaded with heparin, was identified to be the best condition
for a prospective chemokine delivery system, as the highest amount
of CXCL12 was bound and the strongest effects on cell migration
were detected. However, maintaining the balance between chemo-
kine and codelivered heparin is crucial to success and multiple factors
involving scavenging effects, side reactivity, and supply ethics need to
be taken into consideration. Even though the synthetic compounds
tested in this study could not compete with the natural product,
extensive progress has been made in carbohydrate chemistry within
the past years, and the development of compounds displaying the
appropriate interaction sites for chemokine binding are subject to the
near future (Mohamed & Coombe, 2017). This will have many
benefits, as synthetic compounds provide higher structural control
and allow fine-tuning of the protein binding affinity. One might
imagine the creation of a more stable gradient by modulating the
strength of the affinity interactions (Vulic & Shoichet, 2014), either
the GAG component with higher or lower protein-binding affinities or
engineered proteins displaying a stronger or weaker GAG-binding
affinity (Spiller et al., 2019). In both cases, mussel-derived surface-
binding peptides provide a versatile platform that is additionally
modifiable with other bioactive peptides. Combinations of cell
adhesion and HBPs can cooperatively enhance tissue regeneration
(Pagel et al., 2016) and provide a huge toolbox customizable to the
specific needs of future applications.
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investigated in a biotin ELISA-like assay at different pH conditions.
n = 2, * p ≤ 0.05, ns = non significant.
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